Arash Rashidi, MD
- Director, Onco-Nephrology Program, UH Cleveland Medical Center
- Clinical Associate Professor, CWRU School of Medicine
- Specialty: Nephrology, Hypertension, Nephrology-OncoNephrology
-
Location:UH Health Campus Dr
29325 Health Campus Dr
Westlake, OH 44145
- Call: 440-414-9400
Biography: Arash Rashidi, MD
Expertise
Certifications & Memberships
- Nephrology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Fellowship | Interventional Nephrology
Interventional Nephrology - Emory University School Of Medicine (2007 - 2008)
Fellowship | Nephrology
Nephrology - Uh Case Medical Center (2005 - 2007)
Residency | Internal Medicine
Internal Medicine - Fairview Hospital (2002 - 2005)
Medical Education
Urmia Univeristy (West Azerbaijan University of Medical Sciences) (1997)
About
Arash Rashidi, MD, is the director of the Onco-Nephrology Program at University Hospitals and a clinical associate professor of medicine at Case Western Reserve University School of Medicine. He is board-certified in internal medicine and nephrology and hypertension.
Dr. Rashidi earned his medical degree at the Urmia University of Medical Sciences in Urmia, Iran. He did residency training in internal medicine at Shahid Beheshty University of Medical Sciences in Tehran, Iran, and an additional three years at Cleveland Clinic. He went on to complete a nephrology and hypertension fellowship at University Hospitals/Case Western Reserve University followed by an interventional nephrology fellowship at Emory University School of Medicine in Atlanta.
Dr. Rashidi returned to UH in 2014 and became director of Onco-Nephrology Program in 2018. Under his leadership, the Onco-Nephrology Program at UH has become one of the most respected programs in the nation.
Dr. Rashidi has published numerous peer-reviewed articles, abstracts, books and book chapters. He also has served on the editorial board of several prominent medical journals. Additionally, Dr. Rashidi has been an invited speaker/lecturer at several local, national and international meetings and conferences. He has received several awards throughout his career.
Dr. Rashidi is one of the founding members, an executive board member, and past president of the American Society of Onconephrology. Other professional organizations that Dr. Rashidi is a member of include the American College of Physicians, the American Heart Association Council on Kidney in Cardiovascular disease, the American Society of Nephrology, and National Kidney Foundation.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Arash Rashidi did not disclose any Outside Relationships with Industry.